Liu Lisheng

Liu Lisheng

Professor Liu Lisheng graduated from Peking Union Medical College in 1954, and worked in Peking Union Medical College Hospital and Beijing Fuwai Hospital successively. In 1980, he went to Alabama University in Birmingham to engage in postdoctoral research on cardiovascular disease. He has successively served as vice president of Beijing Fuwai Hospital, director of internal medicine, director and professor of hypertension research office.

Social position

Professor Liu Lisheng has been a member of the World Health Organization Expert Committee on cardiovascular diseases, chairman of the China hypertension alliance, chairman of the Chinese society of cardiovascular diseases, director of the international society of hypertension, international researcher of the AHA Hypertension Research Council, and co chairman of the WHO Executive Committee on cardiovascular disease research in developing countries He is currently the director of Beijing Hypertension alliance Institute and professor of Fuwai Hospital, Chinese Academy of Medical Sciences. she took the lead in carrying out large-scale multicenter prospective clinical research in China, leading and organizing the preparation of Chinese guidelines for the prevention and treatment of hypertension. She is a famous expert in cardiovascular medicine at home and abroad, the founder of large-scale clinical trials in China, and an academic leader in the field of hypertension research in China.

Academic works

Published papers: nearly 200 in China and more than 60 in the world. editor in chief of clinical hypertension (won the first prize of national excellent book of health imaging); hypertension. He participated in the compilation of practical Cardiology, modern internal medicine, successful medicine for the elderly, cardiac emergency, treatment practice of hypertension, large-scale authoritative clinical trial research, etc.

Research direction

Training graduate students

More than 40 doctoral and master's degree students have been trained.

Undertaking the project

Systolic hypertension prospective research project 1 (Syst-China) (National Seventh Five year project and international collaboration - Belgium) (completed); relationship between nutrition and blood pressure (animal experiment part) (National Seventh Five year project) (completed); clinical application of atrial peptide (National Seventh Five year project) (completed); relationship between urinary electrolyte and blood pressure (USA); follow up study on antihypertensive treatment after stroke (patss) Tudy (National Seventh Five Year Plan Project and international collaboration Belgium) (completed and in the process of re Statistics); research on insulin resistance in hypertension (National Natural Science Foundation) (completed); research on the relationship between calcium and essential hypertension (completed); clinical evaluation of long-term efficacy of drug and non drug treatment of hypertension (National eighth five year plan project) (completed); China Acute myocardial infarction study 1 (CCS -) (international collaboration Oxford, UK) (completed); ambulatory blood pressure guided antihypertensive therapy clinical study (APTH) (international collaboration project Belgium) (completed); Chinese acute ischemic stroke antiplatelet therapy clinical trial (CAST) (international collaboration Oxford, UK) (completed); Prospective study of low cholesterol natural population (international collaboration project Belgium) (completed) Project Belgium (completed), PEP (World Health Organization, Canada), progress (international cooperation project Australia, New Zealand, Japan) This project is supported by the international cooperation project (UK), the international cooperation project (international cooperation project) and the international cooperation project (international cooperation project) - Canada Unstable angina pectoris intervention study registration trial (oasis rresitter) (International Cooperation Project - Canada) Objective: To evaluate the effect of low molecular weight heparin (LMWH) on the pathogenesis of essential hypertension in large population. Methods: a total of 40 patients with essential hypertension were enrolled in this study The clinical study of metabolic regulation in the treatment of acute myocardial infarction (creatstudy) And other countries); diabetes intervention clinical research (advance) (International Cooperation Project - Australia, New Zealand, UK Warfarin in the treatment of peripheral vascular disease (wavestudy) (International Cooperation Project - Canada) Other countries)

achievements

In the year of prevention and treatment of hypertension, he won the second level achievement award of the Ministry of health; in the year of diagnosis and treatment of secondary hypertension, he won the achievement award of the medical college; in the year of automatic control of pressure lifting drugs, he won the first prize of scientific and technological progress of the medical college. the research year of Takayasu arteritis and secondary hypertension won the first grade achievement award of the Ministry of health; SHR of spontaneously hypertensive rats; the breeding year of shrspwky won the first grade award of scientific and technological progress of the medical college; the research year of the relationship between nutritional components and hypertension and stroke won the third grade award of scientific and technological progress of the medical college; the research year of insulin resistant platelet free calcium and primary hypertension won the scientific and technological progress award of the medical college He won the second prize of the Ministry of health for the prospective research on the treatment of senile systolic hypertension in, the third prize of the national science and Technology Progress Award in, the first prize of the Ministry of health for the science and Technology Progress Award in CCS -, and the second prize of the national science and Technology Progress Award in CCS -.

Social contribution

Liu Lisheng: a lifelong relationship with the research of hypertension. One of them is Professor Liu Lisheng, President of the world hypertension Federation. Professor Liu Lisheng, as a Chinese woman, can be a world leader in the field of Western medicine of hypertension. What a great thing it is. It requires a person to reach a high level in both professional knowledge and character! Professor Liu started the investigation and research work of hypertension with the older generation of cardiovascular medical workers in 1958. It has been nearly 50 years since then. He is a senior figure in the research work of hypertension in China. From her life, we can see the development history of hypertension research since the founding of new China! After graduating from Peking Union Medical College Hospital in 1980, Liu became associate professor of cardiovascular research and director of Peking Union Medical College Hospital. as early as the late 1950s, the older generation of medical workers predicted that with the stability of the country and the improvement of people's living standards, the disease of "high blood pressure" will inevitably increase significantly in China. So in 1959, the "first national cardiovascular conference" was held in Xi'an, and the national hypertension census was proposed. The census results showed that the prevalence of high blood pressure was 5.5%. later, with the development of the current situation, Professor Wu yingkai, he Guanyou, Gao Runquan and Professor Liu of the Academy of Medical Sciences jointly began to recruit students. The first group recruited four people: Wu Su (vice president of Anzhen Hospital), Yao Chonghua, Wang Haiyan and Lai Shenghan (engaged in statistical Research). Since then, China has begun to "train talents in an organized way for Chinese epidemic diseases" Management research team began to grow gradually! Professor Liu said that since 1959, China has started the national hypertension census every ten years. From 79 to 80, the prevalence of hypertension was 7.7% among 4 million people in China. In 1991, the prevalence was 11.25%. In 2002, the prevalence suddenly rose to 18.8%. That is to say, there were 160 million people suffering from hypertension among 1.3 billion people in China! First, the number of people suffering from hypertension in rural areas gradually catch up with that in cities, which shows that the development of urbanization in China is very fast! At the same time, we can see that the older generation of medical workers are very far sighted and began to pay attention to the research and prevention of hypertension early. 2: the aging population is also an important reason for the rapid rise of hypertension. Three: the incidence of disease is getting younger, especially in the 35 to 40 year old population. The incidence rate is rising very fast. This is because this group has heavy burden, high pressure, and does not pay much attention to health, and has many bad living habits. don't let blood pressure be "high" two thirds of patients with hypertension damage heart, brain and kidney don't know reporter: what are the fatal complications of hypertension? How to effectively prevent the occurrence of these dangerous situations? Liu Lisheng: for a long time, hypertension has been called "silent killer" by the medical community. This is because hypertension usually has no obvious clinical symptoms, especially in the early stage, it often has no feeling, only a few people will have headache, dizziness, chest tightness and other symptoms, and these symptoms are not unique to hypertension. But long-term hypertension will quietly damage the heart, brain, kidney and other important organs, until the emergence of stroke, such as cerebral hemorrhage, cerebral thrombosis; myocardial infarction, heart failure; renal failure and other serious complications, threatening human life. to prevent the occurrence of these fatal complications, the most important thing is to detect the risk factor of hypertension as soon as possible and control it to the normal range, that is, 140 / 90 mmHg. But most of the patients were careless and not satisfied

Chinese PinYin : Liu Li Sheng